HSA
CSTL icon

Hussman Strategic Advisors’s Castle Biosciences CSTL Stock Holding History

Hussman Strategic Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,000
Closed -$420K – 235
2025
Q1 		$420K Sell
21,000
-52,500
-71% -$1.3M 0.1% 199
2024
Q4 		$1.96M Buy
+73,500
New +$2.24M 0.58% 67

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Hussman Strategic Advisors's CSTL Position: Q2 2025 in Review

Hussman Strategic Advisors sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 21,000 shares — an estimated $420K sold.

Hussman Strategic Advisors first reported a position in CSTL in Q4 2024 and held it in 2 quarters. The position peaked at $1.96M in Q4 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Hussman Strategic Advisors reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 21,000 Castle Biosciences shares in Q2 2025, an estimated $420K.
  • Hussman Strategic Advisors first reported a position in Castle Biosciences in Q4 2024 and held it in 2 quarters.
  • Hussman Strategic Advisors's Castle Biosciences position peaked at $1.96M in Q4 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Hussman Strategic Advisors's 13F filing for Q2 2025, filed 5 Aug 2025.